

GenMark Diagnostics, Inc.  
Form 10-Q/A  
December 02, 2011  
Table of Contents

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 10-Q/A**  
**Amendment No. 1**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended March 31, 2011

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number: 001-34753

**Genmark Diagnostics, Inc.**

(Exact name of registrant as specified in its charter)

<b>Delaware</b> (State or other jurisdiction of incorporation or organization)	<b>27-2053069</b> (I.R.S. Employer Identification No.)
<b>5964 La Place Court, Suite 100, Carlsbad, California</b> (Address of principal executive offices)	<b>92008-8829</b> (Zip code)
<b>Registrant's telephone number, including area code: 760-448-4300</b>	

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer <input type="checkbox"/>	Accelerated filer <input type="checkbox"/>
Non-accelerated filer <input checked="" type="checkbox"/>	Smaller reporting company <input type="checkbox"/>

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

The number of outstanding shares of the registrant's common stock on April 30, 2010 was 12,337,489.

**Table of Contents**

**EXPLANATORY NOTE**

This Amendment No. 1 on Form 10-Q/A (the "Amendment") amends our Quarterly Report on Form 10-Q for the quarter ended March 31, 2011, as filed with the Securities and Exchange Commission (the "SEC") on May 13, 2011 (the "Original Filing"). The Original Filing is being amended solely to (i) correct the reporting of the license of certain intellectual property rights, which should have been recorded as both an asset and a liability in our financial statements for the year and quarter ended December 31, 2010 and March 31, 2011, respectively, (ii) reclassify \$667,000 of our loan payable to the current portion of long-term debt at March 31, 2011, (iii) reclassify certain immaterial revenues and expenses in the Condensed Consolidated Statements of Operations for the periods presented herein, with no net impact to operating income, net loss, statements of cash flows or balance sheets, as described below, and (iv) correct the number of shares of common stock outstanding at December 31, 2010. Accordingly, Items 1, 2 and 4 of Part I of the Original Filing are hereby amended and restated in their entirety.

Subsequent to the issuance of our 2010 audited financial statements, we concluded that a contract for the license of certain intellectual property rights should have been recorded as both an asset and a liability in the financial statements for the period ended March 31, 2011. We have recorded this contract which results in an increase of \$1,389,000 to intangible assets for the period ended March 31, 2011. The current and long-term portion of the liability for the contract for which payment was not due at March 31, 2011 was \$1,043,000 and \$346,000, respectively, as of March 31, 2011.

Subsequent to the issuance of our 2010 audited financial statements, we further concluded that certain revenues and expenses were classified incorrectly in our Condensed Consolidated Statements of Operations for the past periods presented herein, with no net impact to operating income, net loss, statements of cash flows or balance sheets. These corrections result in reductions to cost of sales of \$68,301 in the quarter ended March 31, 2010 and \$142,501 in the quarter ended March 31, 2011 and corresponding changes to revenues and increases to sales and marketing and research and development expenses. The corrections were made to reclassify freight revenue which was originally netted against freight expense, reclassify samples and freight expense to sales and marketing expense, and to allocate wages for employees spent on non-production activities to research and development and general and administrative expense from cost of sales expense. Additionally, based on a loan amendment dated March 2011, the Company should have reclassified \$667,000 of its loan payable to current portion of long-term debt at March 31, 2011. The original filing reflected the full loan payable amount as long-term debt.

In connection with the filing of this Amendment and pursuant to the rules of the SEC, we are including with this Amendment certain currently dated certifications as exhibits to this Form 10-Q/A under Item 6 of Part II hereof.

Except as described above, no other changes have been made to the Original Filing. The Original Filing, as amended by this Amendment, continues to speak as of the date of the Original Filing, and we have not updated the disclosures contained therein to reflect any events which occurred at a date subsequent to the filing of the Original Filing. Accordingly, this Amendment should be read in conjunction with the Original Filing and our filings made with the SEC subsequent to the date of the Original Filing.

**Table of Contents**

**TABLE OF CONTENTS**

	<b>Page</b>
<b><u>PART I - FINANCIAL INFORMATION</u></b>	
Item 1. <u>Financial Statements</u>	1
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	13
Item 4. <u>Controls and Procedures</u>	19
<b><u>PART II - OTHER INFORMATION</u></b>	
Item 6. <u>Exhibits</u>	20

**Table of Contents****PART I - FINANCIAL INFORMATION****ITEM 1. FINANCIAL STATEMENTS****GENMARK DIAGNOSTICS, INC.****CONDENSED CONSOLIDATED BALANCE SHEETS****(Unaudited)**

	As of March 31, 2011	As of December 31, 2010
<b>Current assets</b>		
Cash and cash equivalents	\$ 17,054,095	\$ 18,329,079
Accounts receivable, net	762,272	677,648
Inventories, net	871,033	896,809
Other current assets	382,194	2,193,160
<b>Total current assets</b>	<b>19,069,594</b>	<b>22,096,696</b>
Property and equipment, net	2,762,362	2,702,478
Intangible assets, net	1,457,042	1,459,980
Other long-term assets	55,355	55,355
<b>Total assets</b>	<b>\$ 23,344,353</b>	<b>\$ 26,314,509</b>
<b>Current liabilities</b>		
Accounts payable	\$ 1,651,985	\$ 823,242
Accrued compensation	1,019,545	1,171,989
Current portion of long-term debt	667,000	
Other current liabilities	2,804,011	1,944,928
<b>Total current liabilities</b>	<b>6,142,541</b>	<b>3,940,159</b>
<b>Long-term liabilities</b>		
Loan payable	1,333,000	
Other non-current liabilities	968,644	1,306,932
<b>Total liabilities</b>	<b>\$ 8,444,185</b>	<b>\$ 5,247,091</b>
<b>Stockholders equity</b>		
Common stock, \$0.0001 par value; 100,000,000 authorized; 11,738,233 and 11,728,233 issued and outstanding as of March 31, 2011 and December 31, 2010, respectively	1,172	1,172
Preferred stock, \$0.0001 par value; 5,000,000 authorized, none issued		
Additional paid-in capital	166,483,672	166,009,084
Accumulated deficit	(151,134,719)	(144,492,881)
Accumulated other comprehensive loss	(449,957)	(449,957)
<b>Total stockholders equity</b>	<b>14,900,168</b>	<b>21,067,418</b>
<b>Total liabilities and stockholders equity</b>	<b>\$ 23,344,353</b>	<b>\$ 26,314,509</b>

See accompanying notes to unaudited condensed consolidated financial statements.



**Table of Contents****GENMARK DIAGNOSTICS, INC.****CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS****(Unaudited)**

	<b>Three Months Ended March 31,</b>	
	<b>2011</b>	<b>2010</b>
<b>Product Revenue</b>	\$ 692,739	\$ 384,249
License and other revenue	65,130	25,534
<b>Total revenue</b>	757,869	409,783
Cost of sales	1,500,955	499,095
<b>Gross loss</b>	(743,086)	(89,312)
<b>Operating expenses</b>		
Sales and marketing	1,218,548	1,108,730
General and administrative	2,123,054	2,180,494
Research and development	2,564,342	1,468,904
<b>Total operating expenses</b>	5,905,944	4,758,128
<b>Loss from operations</b>	(6,649,030)	(4,847,440)
<b>Other income</b>		
Other income (expense)	11,899	(1,110)
Interest income	6,258	4,654
<b>Total other income</b>	18,157	3,544
<b>Loss before income taxes</b>	(6,630,873)	(4,843,896)
Provision for income taxes	(10,968)	(5,049)
<b>Net loss</b>	\$ (6,641,841)	\$ (4,848,847)
Net loss per share, basic and diluted	\$ (0.56)	\$ (0.68)
Weighted average number of shares outstanding	11,771,014	7,113,922
<b>Condensed consolidated statements of comprehensive loss three and three months ended March 31, 2011 and 2010</b>		
Net loss	\$ (6,641,841)	\$ (4,848,945)
Foreign currency translation adjustment		(34,647)
Comprehensive loss	\$ (6,641,841)	\$ (4,883,592)

See accompanying notes to unaudited condensed consolidated financial statements.

**Table of Contents****GENMARK DIAGNOSTICS, INC.****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS****(Unaudited)**

	<b>Three Months Ended March 31,</b>	
	<b>2011</b>	<b>2010</b>
<b>Cash flows from operating activities:</b>		
Net loss	\$ (6,641,841)	\$ (4,848,945)
<b>Adjustments to reconcile net loss to net cash used in operating activities:</b>		
Depreciation and amortization	288,771	318,369
Change in allowance for doubtful accounts, net of write-offs	(47,785)	
Change in allowance for excess and obsolete inventory	(546)	
Share-based compensation	474,588	347,530
<b>Changes in operating assets and liabilities:</b>		
Trade accounts receivable	(36,839)	(71,316)
Inventories	26,322	(65,138)
Other current assets	1,810,966	(469,561)
Accounts payable	667,559	(316,564)
Accrued compensation	(152,444)	279,184
Accrued and other liabilities	520,798	(155,724)
<b>Net cash used in operating activities</b>	<b>(3,090,451)</b>	<b>(4,982,165)</b>
<b>Investing activities:</b>		
Purchases of property and equipment	(184,533)	(137,440)
<b>Net cash used in investing activities</b>	<b>(184,533)</b>	<b>(137,440)</b>
<b>Financing activities:</b>		
Proceeds of loan payable	2,000,000	
Proceeds from stock option exercises		4,734
<b>Net cash provided by financing activities</b>	<b>2,000,000</b>	<b>4,734</b>
<b>Effect of foreign exchange rate changes</b>		<b>(46,935)</b>
<b>Net decrease in cash and cash equivalents</b>	<b>(1,274,984)</b>	<b>(5,114,871)</b>
<b>Cash and cash equivalents at beginning of period</b>	<b>18,329,079</b>	<b>16,482,818</b>
<b>Cash and cash equivalents at end of period</b>	<b>\$ 17,054,095</b>	<b>\$ 11,321,012</b>
<b>Noncash investing and financing activities:</b>		
Reclassification of deposits on systems in other current assets		\$ 285,284
IPO costs incurred but not paid included in accounts payable		1,537,192
Property and equipment costs incurred but not paid included in accounts payable	\$ 161,184	

See accompanying notes to unaudited condensed consolidated financial statements.



---

**Table of Contents**

**Genmark Diagnostics, Inc.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

**1. Organization and basis of presentation**

Genmark Diagnostics, Inc. (the Company or GenMark) is a molecular diagnostics company focused on developing and commercializing the Company's proprietary e-sensor technology. On February 12, 2010, the Company was established to serve as the parent company of Osmetech plc (Osmetech) upon a corporate reorganization and initial public offering (IPO). On June 3, 2010, the Company completed an IPO for 4,600,000 shares. Immediately prior to the completion of the IPO, the Company underwent a corporate reorganization whereby the ordinary shares of Osmetech were exchanged by its shareholders for the common stock of the Company on a 230 for 1 basis.

As the reorganization is deemed to be a transaction under common control, GenMark accounted for the reorganization in a manner similar to a pooling-of-interests, meaning:

- (i) assets and liabilities were carried over at their respective carrying values;
- (ii) common stock was carried over at the nominal value of the shares issued by GenMark;
- (iii) additional paid-in capital represents the difference between the nominal value of the shares issued by GenMark, and the total of the additional paid-in capital and nominal value of Osmetech's shares cancelled pursuant to the described reorganization; and
- (iv) the accumulated deficit represents the aggregate of the accumulated deficit of Osmetech and the Company.

Once the reorganization became effective, all stock options granted under the Osmetech plc 2003 U.S. Equity Compensation Plan, Long Term Incentive Awards and all warrants issued were exchanged for options and warrants exercisable for the common stock of the Company.

The preferred stock may be issued from time to time in one or more series.

In these consolidated financial statements, the Company means Osmetech when referring to periods prior to the corporate reorganization and IPO.

The Company evaluated subsequent events through May 13, 2011, being the date of issuance of the unaudited condensed consolidated financial statements.

The accompanying financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses from operations since its inception and has an accumulated deficit of \$151,134,719 at March 31, 2011. Cash and cash equivalents at March 31, 2011 were \$17,054,095.

Management expects operating losses to continue through the foreseeable future until the Company has expanded its product offerings and increased its product revenues to an extent covers the fixed cost base of the business. The Company's management has prepared cash flow forecasts which indicate, based on the current cash resources available and the availability of unutilized credit facilities, that the Company has sufficient capital to fund its operations for at least the next twelve months.

The Company has prepared the accompanying unaudited condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for audited financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments considered necessary for a fair presentation, have been included. Operating results for the three months ended March 31, 2011 are not necessarily indicative of the results that may be expected for the year ending December 31, 2011. The information presented in the condensed consolidated financial statements and related footnotes at March 31, 2011, and for the three months ended March 31, 2011 and 2010, is unaudited and the condensed consolidated balance sheet amounts and related footnotes at December 31, 2010 have been derived from our audited financial statements. For further information, refer to the consolidated financial statements and accompanying footnotes included in our annual report Form 10-K filed with the Securities and Exchange Commission (SEC) on March 14, 2011.



**Table of Contents**

**Genmark Diagnostics, Inc.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

The Company operates in one reportable segment, and substantially all of the Company's operations and assets are in the United States of America.

*Principles of Consolidation*-The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

***Recent Accounting Pronouncements***

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. We believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.

***Fair Value of Financial Instruments***

The Company's financial instruments consist of cash equivalents, accounts receivable, accounts payable and loan payable. The carrying amounts of accounts receivable, accounts payable and the loan payable are considered reasonable estimates of their fair value, due to the short maturity of these instruments. There were no significant financial instruments requiring one-time or recurring measurements of fair value during the three months ended March 31, 2011.

Accounting literature provides a fair value hierarchy, which classifies fair value measurements based on the inputs used in measuring fair value. These inputs include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions. There were no transfers of items between Levels 1, 2 or 3.

***Cash and cash equivalents:*** The carrying amounts reported in the balance sheets for cash and cash equivalents are stated at their fair market value. Cash and cash equivalents are classified as Level 1.

***Loan payable:*** The carrying amount reported in the balance sheets for the loan payable is considered a reasonable estimate of fair value, based on the short maturity and comparable terms for similar credit facilities. The loan payable is classified as Level 2.

***Non-recurring measurements:*** The Company measures the fair value of its long-lived assets on a periodic basis when it appears that there may be requirement to do so, such as an indication of impairment. There was no impairment recorded for the three months ended March 31, 2011.

***Income Taxes***

Current income tax expense is the amount of income taxes expected to be payable for the current year. A deferred income tax liability or asset is established for the expected future tax consequences resulting from the differences in financial reporting and tax bases of assets and liabilities. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. A full valuation allowance has been recorded against the Company's deferred tax assets due to the uncertainty surrounding the Company's ability to utilize these assets in the future. The Company provides for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement standards prescribed by the authoritative guidance on income taxes. Amounts for uncertain tax positions are adjusted in periods when new information becomes available or when positions are effectively settled. The Company recognizes accrued interest and penalties related to uncertain tax positions as a component of income tax expense.

**Table of Contents****Genmark Diagnostics, Inc.****Notes to Unaudited Condensed Consolidated Financial Statements****2. Share-Based Compensation**

The Company recognizes share-based compensation expense related to share options, warrants and restricted stock issued to employees, directors and consultants in exchange for services. The compensation expense is based on the fair value of the awards, which are determined by utilizing various assumptions regarding the underlying attributes of the options and shares. The estimated fair value of options granted and restricted stock, net of forfeitures expected to occur during the vesting period, is amortized as compensation expense on a straight line basis over the period the vesting occurs. The share-based compensation expense is recorded in cost of sales, sales and marketing, research and development and general and administrative expenses based on the employee's or consultant's respective function. The option and warrant-related expense is derived from the Black-Scholes Option Pricing Model that uses several judgment based variables to calculate the expense. The inputs include the expected life of the option or warrant, the expected volatility and other factors. The compensation expense related to the restricted stock is calculated as the difference between the fair market value of the stock on the date of grant, less the cost to acquire the shares, which is \$0.0001 per share.

On June 3, 2010, the Company exchanged all of the outstanding options under the Osmetech plc 2003 U.S. Equity Compensation Plan (the "U.S. Plan") for options under the 2010 Equity Incentive Plan (the "Plan"). The options were exchanged using an exchange ratio of 230 options to purchase shares of Osmetech plc to one share of the Company and was accounted for as a modification of the share-based payment arrangement. There was no additional compensation cost recorded related to the exchange as there was no change in the economic value of the options exchanged.

Employee participation in the Plan is at the discretion of the compensation committee or senior management of the Company. All options granted since June 3, 2010 are exercisable at a price equal to the average closing quoted market price of the Company's shares on the NASDAQ on the date of grant. Options granted prior to June 3, 2010 under the Osmetech plc 2003 U.S. Equity Compensation Plan were exercisable at a price equal to the average closing quoted market price of the Osmetech plc's shares on the Alternative Investment Market of the London Stock Exchange on the date of the grant as adjusted for the exchange ratio to the Company's shares as described above. Options generally vest between 1 and 4 years.

Options are generally exercisable for a period up to 10 years after grant and are forfeited if the employee leaves the Company before the options vest. As of March 31, 2011, 701,957 shares remained available for future grant of awards under the Plan. Restricted stock grants reduce the amount of stock options available for grant under the 2010 Plan and are excluded from the table below.

The following table summarizes stock option activity during the three months ended March 31, 2011:

	Number of Share options	Weighted average exercise price
Outstanding at December 31, 2010	1,107,920	\$ 6.40
Granted	226,500	4.37
Exercised		
Cancelled	(19,445)	(0.37)
Outstanding at March 31, 2011	1,314,975	\$ 6.06
Exercisable at March 31, 2011	516,596	\$ 7.12

As of March 31, 2011, there were 1,314,975 options that are vested or expected to vest and these options have a remaining weighted average contractual term of 8.63 years, and an aggregate intrinsic value of \$0.

During the three months ended March 31, 2011, the Company granted 130,800 shares of restricted stock to senior management employees and 10,000 shares of restricted stock to an outside consultant. The restricted stock granted to senior management employees vests over a four year period except for 4,000 shares of restricted stock issued to one employee as part of a separation agreement that vests May 31, 2011. The

Edgar Filing: GenMark Diagnostics, Inc. - Form 10-Q/A

restricted stock granted to the outside consultant vested on March 1, 2011 commensurate with the period of service rendered to the Company.

**Table of Contents****Genmark Diagnostics, Inc.****Notes to Unaudited Condensed Consolidated Financial Statements**

**Valuation of Share-Based Awards** The Black-Scholes option pricing model was used for estimating the grant date fair value of stock options granted during the three months ended March 31, 2011 with the following assumptions:

Expected volatility (%)	70.0
Expected life (years)	6.08
Risk free rate (%)	2.51
Expected dividend yield (%)	0

**3. Net Loss Per Common Share**

Basic net loss per share is computed by dividing loss available to common shareholders (the numerator) by the weighted average number of common shares outstanding during the period (the denominator). Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted loss per share is calculated in a similar way to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the dilutive potential shares had been issued unless the effect would be anti-dilutive. As the Company had a net loss in each of the periods presented, basic and diluted net loss per ordinary share are the same.

The computations of diluted net loss per share did not include the effects of the following securities as the inclusion of these items would have been anti-dilutive:

	<b>Three months ended March 31,</b>	
	<b>2011</b>	<b>2010</b>
Share options	1,314,975	960,624
Warrants	88,317	88,317
Restricted Stock vested; not issued or outstanding	61,057	
	1,464,349	1,048,941

**Common Stock Warrants** During 2009, the Company issued warrants to purchase 132,475 of Osmetech's ordinary shares with an exercise price of £4.60 per share, and warrants to purchase 88,317 of Osmetech's ordinary shares with an exercise price of £6.90 per share to a director for services to the Company in connection with the share offering completed in 2009. Pursuant to the terms of the warrant, the warrant to purchase 132,475 was cancelled upon the closing of the IPO in June 2010. At the same time, the warrant to purchase 88,317 of Osmetech's ordinary shares was converted to warrants to purchase 88,317 shares of the Company's common stock at an exercise price of \$9.98. These warrants were fully vested and exercisable upon issue, and shall continue to be exercisable up to and including the earlier to occur of (i) 60 days after the director leaving the Company's board of directors (for whatever reason) and (ii) June 30, 2012.

**4. Intangible assets**

Intangible assets, consisting of patents, purchased and licensed intellectual property, as of March 31, 2011 and December 31, 2010 comprise the following:

Edgar Filing: GenMark Diagnostics, Inc. - Form 10-Q/A

	March 31, 2011			December 31, 2010		
	Gross carrying amount	Accumulated amortization	Net carrying amount	Gross carrying amount	Accumulated amortization	Net carrying amount
Patents and trademarks	\$	\$	\$	\$ 438,032	\$ (438,032)	\$
Intellectual property				877,140	(877,140)	
Licensed intellectual property	2,473,068	(1,016,026)	1,457,042	2,640,518	(1,180,538)	1,459,980
	\$ 2,473,068	\$ (1,016,026)	\$ 1,457,042	\$ 3,955,690	\$ (2,495,710)	\$ 1,459,980

Licenses have a weighted average remaining amortization period of 10.2 years as of March 31, 2011. Amortization expense for intangible assets amounted to \$2,938 and \$15,438 for the three months ended March 31, 2011 and 2010, respectively. Estimated future amortization expense for these licenses is as follows:

Years Ending March 31,	
2012	\$ 81,200
2013	81,200
2014	81,200
2015	81,200
2016	80,575
Thereafter	1,051,667
<b>Total</b>	<b>\$ 1,457,042</b>

**Table of Contents****Genmark Diagnostics, Inc.****Notes to Unaudited Condensed Consolidated Financial Statements****5. Property and Equipment, net**

Property and equipment was comprised of the following as of March 31, 2011 and December 31, 2010:

	<b>March 31, 2011</b>	<b>December 31, 2010</b>
Property and equipment at cost:		
Plant and machinery	\$ 2,473,579	\$ 2,451,775
Rental systems	3,125,399	2,821,665
Office equipment	1,548,235	1,541,544
Leasehold improvements	611,021	597,523
Total property and equipment at cost	7,758,234	7,412,507
Less accumulated depreciation	(4,995,872)	(4,710,029)
Net property and equipment	\$ 2,762,362	\$ 2,702,478

Depreciation expense amounted to \$285,833 and \$198,687 for the three months ended March 31, 2011 and 2010, respectively.



---

**Table of Contents**

**Genmark Diagnostics, Inc.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

**6. Loan payable**

In March 2010, the Company entered into a loan and security agreement with Square 1 Bank, pursuant to obtaining a credit facility consisting of a revolving line of credit in the amount of up to \$2 million and an equipment term loan in the amount of up to \$2 million. Based upon certain financial covenants, interest on the revolving line of credit will be either (i) the greater of (a) the bank's prime rate (3.25% as of March 31, 2011) plus 2.75%, or (b) 6%; or (ii) the greater of (a) the bank's prime rate plus 3.75%, or (b) 7%. In addition, based upon certain financial covenants, interest on the equipment term loan will be either (i) the greater of (a) the bank's prime rate plus 3.25%, or (b) 6.50%; or (ii) the greater of (a) the bank's prime rate plus 4.25%, or (b) 7.50%. The revolving line matures in July 2011 and the term loan matures in July 2013. In March 2011, the loan and security agreement was amended, whereby the line of credit availability was increased to \$3 million and the maturity was extended to July 2012. The term loan was modified to allow invoices up to 360 days to qualify to be submitted for credit extension. There were no other changes to these two loans.

In March 2011, an additional loan was made available under the amended loan and security agreement for up to \$1.0 million to finance equipment purchases. Based upon certain financial covenants, interest on this equipment term loan will be either (i) the greater of (a) the bank's prime rate plus 3.25%, or (b) 6.50%; or (ii) the greater of (a) the bank's prime rate plus 4.25%, or (b) 7.50%. This term loan matures March 2014.

As of March 31, 2011, the Company had no outstanding loans on the line of credit or the 2011 equipment loan and had drawn \$2.0 million to finance 2010 equipment purchases and tenant improvements to its Carlsbad facility against the original 2010 equipment term loan. The loan bears an interest rate of 6.5%.

Pursuant to the terms of the loan and security agreement, we are required to maintain a ratio of liquidity to bank indebtedness equal to at least 1.50 to 1.00. In addition, the loan and security agreement includes several restrictive covenants, including requirements that we obtain the consent of Square 1 Bank prior to entering into any change of control event unless all debt is repaid to Square 1 Bank prior to the change of control event, incurring other indebtedness or liens with respect to our property, making distributions to our stockholders, making certain investments or entering into certain transactions with affiliates and other restrictions on storing inventory and equipment with third parties. The agreement also limits the amount we can borrow under the term loan to license genetic biomarkers to \$500,000. To secure the credit facility, we granted Square 1 Bank a first priority security interest in our assets and intellectual property rights. We are currently in compliance with all ratios and covenants.

**7. Income taxes**

The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.

As of March 31, 2011, the Company has recorded a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the Company's ability to utilize these assets in the future. Provision for income tax was \$11,000 and \$5,000 for the three months ended March 31, 2011 and 2010, respectively. Due to the Company's losses it only records tax provision or benefit related to minimum tax payments or refunds and interest and penalties related to its uncertain tax positions.

The total amount of unrecognized tax benefits was \$382,000 as of March 31, 2011 which would impact the effective tax rate if recognized. The gross liability for income taxes related to unrecognized tax benefits is included in other long-term liabilities in the Company's condensed consolidated balance sheets.

The total balance of accrued interest related to uncertain tax positions was \$104,770 as of March 31, 2011. The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense. The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months.

## Edgar Filing: GenMark Diagnostics, Inc. - Form 10-Q/A

The Company is subject to taxation in the U.S., UK based on its legacy operations, and in various state jurisdictions. As of March 31, 2011 the Company's tax years after 2007 are subject to examination by the UK tax authorities. Except for net operating losses generated in prior years carrying forward to the current year, as of March 31, 2011, the Company is no longer subject to U.S. federal, state, local or foreign examinations by tax authorities for years before 2006.

### **8. Unrecorded licensing agreement and reclassifications**

Subsequent to the issuance of the 2010 audited financial statements, the Company concluded that a contract for the license of certain intellectual property rights should have been recorded as both an asset and a liability in the financial statements for the periods ended December 31, 2010 and March 31, 2011. The Company has recorded this contract which results in an increase of \$1,389,000 to intangible assets for the year ended December 31, 2010 and for the period ended March 31, 2011, respectively. The current and long-term portion of the liability for the contract was as of December 31, 2010 and March 31, 2011 was \$695,000 and \$694,000 and \$1,043,000 and \$346,000, respectively. Additionally, based on a loan amendment dated March 2011, the Company should have reclassified \$667,000 of its loan payable to current portion of long-term debt at March 31, 2011.

Subsequent to the issuance of the 2010 audited financial statements, the Company further concluded that certain revenues and expenses were classified incorrectly in its Condensed Consolidated Statements of Operations for the past periods presented herein, with no net impact to operating income, net loss, statements of cash flows or balance sheets. The Company has corrected these immaterial misstatements. These corrections result in reductions to cost of sales of \$142,501 and \$68,301 in the quarters ending March 31, 2011 and 2010, respectively, and corresponding changes to revenues, sales and marketing, general and administrative and research and development expenses.

**Table of Contents**

The following tables reconcile the As Reported financial statements with the As Corrected financial statements.

**GENMARK DIAGNOSTICS, INC.****CONDENSED CONSOLIDATED BALANCE SHEETS****(Unaudited)**

	As Reported December 31, 2010	Adjustments	As Corrected December 31, 2010
<b>Current assets</b>			
Cash and cash equivalents	\$ 18,329,079		\$ 18,329,079
Accounts receivable, net	677,648		677,648
Inventories	896,809		896,809
Other current assets	2,193,160		2,193,160
<b>Total current assets</b>	<b>22,096,696</b>		<b>22,096,696</b>
Property and equipment, net	2,702,478		2,702,478
Intangible assets, net	70,980	1,389,000	1,459,980
Other long-term assets	55,355		55,355
<b>Total assets</b>	<b>\$ 24,925,509</b>	<b>\$ 1,389,000</b>	<b>\$ 26,314,509</b>
<b>Current liabilities</b>			
Accounts payable	\$ 823,242		\$ 823,242
Accrued compensation	1,171,989		1,171,989
Other current liabilities	1,249,928	695,000	1,944,928
<b>Total current liabilities</b>	<b>3,245,159</b>	<b>695,000</b>	<b>3,940,159</b>
<b>Long-term liabilities</b>			
Loan payable			
Other non-current liabilities	612,932	694,000	1,306,932
<b>Total liabilities</b>	<b>\$ 3,858,091</b>	<b>\$ 1,389,000</b>	<b>\$ 5,247,091</b>
<b>Stockholders equity</b>			
Preferred stock, \$0.0001 par value; 5,000,000 authorized, none issued			
Common stock, \$0.0001 par value; 100,000,000 authorized 11,728,233 issued and outstanding	1,172		1,172
Additional paid-in capital	166,009,084		166,009,084
Accumulated deficit	(144,492,881)		(144,492,881)
Accumulated other comprehensive loss	(449,957)		(449,957)
<b>Total stockholders equity</b>	<b>21,067,418</b>		<b>21,067,418</b>
<b>Total liabilities and stockholders equity</b>	<b>\$ 24,925,509</b>	<b>\$ 1,389,000</b>	<b>\$ 26,314,509</b>

**Table of Contents****GENMARK DIAGNOSTICS, INC.****CONDENSED CONSOLIDATED BALANCE SHEETS**

(Unaudited)

	<b>As Reported March 31, 2011</b>	<b>Adjustments</b>	<b>As Corrected March 31, 2011</b>
<b>Current assets</b>			
Cash and cash equivalents	\$ 17,054,095		\$ 17,054,095
Accounts receivable, net	762,272		762,272
Inventories	871,033		871,033
Other current assets	382,194		382,194
<b>Total current assets</b>	<b>19,069,594</b>		<b>19,069,594</b>
Property and equipment, net	2,762,362		2,762,362
Intangible assets, net	68,042	1,389,000	1,457,042
Other long-term assets	55,355		55,355
<b>Total assets</b>	<b>\$ 21,955,353</b>	<b>\$ 1,389,000</b>	<b>\$ 23,344,353</b>
<b>Current liabilities</b>			
Accounts payable	\$ 1,651,985		\$ 1,651,985
Accrued compensation	1,019,545		1,019,545
Current portion of long-term debt		667,000	667,000
Other current liabilities	1,761,011	1,043,000	2,804,011
<b>Total current liabilities</b>	<b>4,432,541</b>	<b>1,710,000</b>	<b>6,142,541</b>
<b>Long-term liabilities</b>			
Loan payable	2,000,000	(667,000)	1,333,000
Other non-current liabilities	622,644	346,000	968,644
<b>Total liabilities</b>	<b>\$ 7,055,185</b>	<b>\$ 1,389,000</b>	<b>\$ 8,444,185</b>
<b>Stockholders equity</b>			
Preferred stock, \$0.0001 par value; 5,000,000 authorized, none issued			
Common stock, \$0.0001 par value; 100,000,000 authorized 11,738,233 issued and outstanding	1,172		1,172
Additional paid-in capital	166,483,672		166,483,672
Accumulated deficit	(151,134,719)		(151,134,719)
Accumulated other comprehensive loss	(449,957)		(449,957)
<b>Total stockholders equity</b>	<b>14,900,168</b>		<b>14,900,168</b>
<b>Total liabilities and stockholders equity</b>	<b>\$ 21,955,353</b>	<b>\$ 1,389,000</b>	<b>\$ 23,344,353</b>

**Table of Contents****GENMARK DIAGNOSTICS, INC.****CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

(Unaudited)

	As Reported		Adjustments		As Corrected	
	Three Months Ended		Three Months Ended		Three Months Ended	
	March 31,		March 31,		March 31,	
	2011	2010	2011	2010	2011	2010
<b>Product Revenue</b>	\$ 692,739	\$ 384,249	\$	\$	\$ 692,739	\$ 384,249
License and other revenue	71,664	15,015	(6,534)	10,519	65,130	25,534
<b>Total revenue</b>	764,403	399,264	(6,534)	10,519	757,869	409,783
Cost of sales	1,643,456	567,396	(142,501)	(68,301)	1,500,955	499,095
<b>Gross loss</b>	(879,053)	(168,132)	(135,967)	(78,820)	(743,086)	(89,312)
<b>Operating expenses</b>						
Sales and marketing	1,130,389	1,058,285	88,159	50,445	1,218,548	1,108,730
General and administrative	2,111,336	2,167,264	11,718	13,230	2,123,054	2,180,494
Research and development	2,528,252	1,453,759	36,090	15,145	2,564,342	1,468,904
<b>Total operating expenses</b>	5,769,977	4,679,308	135,967	78,820	5,905,944	4,758,128
<b>Loss from operations</b>	(6,649,030)	(4,847,440)			(6,649,030)	(4,847,440)
<b>Other income</b>						
Other income (expense)	11,899	(1,110)			11,899	(1,110)
Interest income	6,258	4,654			6,258	4,654
<b>Total other income</b>	18,157	3,544			18,157	3,544
<b>Loss before income taxes</b>	(6,630,873)	(4,843,896)			(6,630,873)	(4,843,896)
Provision for income taxes	(10,968)	(5,049)			(10,968)	(5,049)
<b>Net loss</b>	\$ (6,641,841)	\$ (4,848,945)			\$ (6,641,841)	\$ (4,848,945)
Net loss per share, basic and diluted	\$ (0.56)	\$ (0.68)			\$ (0.56)	\$ (0.68)
Weighted average number of shares outstanding	11,771,014	7,113,922			11,771,014	7,113,922
<b>Condensed consolidated statements of comprehensive loss three and six months ended June 30, 2011 and 2010</b>						
Net loss	\$ (6,641,841)	\$ (4,848,945)			\$ (6,641,841)	\$ (4,848,945)
Foreign currency translation adjustment		(34,647)				(34,647)
<b>Comprehensive loss</b>	\$ (6,641,841)	\$ (4,883,592)			\$ (6,641,841)	\$ (4,883,592)

**Table of Contents****ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

The following discussion of our financial condition and results of operations should be read with our unaudited condensed consolidated financial statements and notes included in Item 1 of this Quarterly Report for the three months ended March 31, 2011, as well as the audited financial statements and notes and Management's Discussion and Analysis of Financial Condition and Results of Operations for the fiscal year ended December 31, 2010, included in our annual report Form 10-K dated March 11, 2011 filed with the SEC. This Management's Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements regarding future events and our future results are based on current expectations, estimates, forecasts, and projections and the beliefs and assumptions of our management including, without limitation, our expectations regarding our results of operations, sales and marketing expenses, general and administrative expenses, research and development expenses, and the sufficiency of our cash for future operations. Words such as we expect, anticipate, target, project, believe, goals, estimate, potential, may, will, expect, might, could, intend, variations of these terms or the negative of those terms and similar expressions are intended to identify these forward-looking statements. Readers are cautioned that these forward-looking statements are predictions and are subject to risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements.

Among the important factors that could cause actual results to differ materially from those indicated by our forward-looking statements are those discussed under the heading Risk Factors in Item 1A of Part I of our Annual Report on Form 10-K for the year ended December 31, 2010 and any risk factors described under the heading Risk Factors in Item 1A of Part II of this Quarterly Report. We do not intend to update these forward looking statements to reflect future events or circumstances.

**Overview**

GenMark Diagnostics, Inc., or GenMark, was formed by Osmetech plc, or Osmetech, in Delaware in February 2010 and had no operations prior to its initial public offering which was completed in June 2010. Immediately prior to the closing of the initial public offering, GenMark acquired all of the outstanding ordinary shares of Osmetech in a reorganization under the applicable laws of the United Kingdom. As a result of the reorganization, all of the issued ordinary shares in Osmetech were cancelled in consideration of (i) the issuance of common stock of GenMark to the former shareholders of Osmetech and (ii) the issuance of new shares in Osmetech to GenMark. Following the reorganization, Osmetech became a subsidiary controlled by GenMark, and the former shareholders of Osmetech began to hold shares of GenMark. Any historical discussion of GenMark relates to Osmetech and its consolidated subsidiaries prior to the reorganization.

We are a molecular diagnostics company focused on developing and commercializing our proprietary eSensor detection technology. Our proprietary electrochemical technology enables fast, accurate and highly sensitive detection of up to 72 distinct biomarkers in a single sample. Our XT-8 system received 510(k) clearance from the Food and Drug Administration, or FDA, and is designed to support a broad range of molecular diagnostic tests with a compact and easy-to-use workstation and self-contained, disposable test cartridges. Within 30 minutes of receipt of an amplified DNA sample, our XT-8 system produces clear and accurate results. Our XT-8 system supports up to 24 independent test cartridges, which can be run independently, resulting in a highly convenient and flexible workflow for our target customers, which are hospitals and reference laboratories.

We have developed four diagnostic tests for use with our XT-8 system and expect to expand this test menu by introducing two to four new tests annually. Our Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, our Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, and our Thrombophilia Risk Test, which detects an individual's increased risk of blood clots, have received FDA clearance. Our eSensor technology has demonstrated 100% accuracy in clinical studies compared to DNA sequencing in our Cystic Fibrosis Genotyping Test, our Warfarin Sensitivity Test and our Thrombophilia Risk Test. We have also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses and is labeled for investigational use only, or IUO. We intend to seek FDA clearance for our Respiratory Viral Panel Test in 2011. We also have a pipeline of several additional potential products in different stages of development or design, including diagnostic tests for an individual's sensitivity to Plavix, a commonly prescribed anti-coagulant, and for mutations in a gene known as K-ras, which is predictive of an individual's response rates to certain prescribed anti-cancer therapies.

**Table of Contents**

We are also developing our next-generation platform, the NexGen system. We are designing the NexGen system to integrate DNA amplification with our eSensor detection technology to enable technicians using the NexGen system to be able to place a raw or minimally prepared patient sample into our test cartridge and obtain results without any additional steps. This sample to answer capability is enabled by the robust nature of our eSensor detection technology, which is not impaired by sample impurities that we believe hinder competing technologies. We are designing our NexGen system to further simplify workflow and provide powerful, cost-effective molecular diagnostics solutions to a significantly expanded group of hospitals and reference laboratories.

Since inception, we have incurred net losses from continuing operations each year, and we expect to continue to incur losses for the foreseeable future. Our losses attributable to continuing operations for the three months ended March 31, 2011 and 2010 were approximately \$6.6 million and \$4.8 million, respectively. As of March 31, 2011, we had an accumulated deficit of \$151.1 million. Our operations to date have been funded principally through sales of capital stock and sales of our previous businesses. We expect to incur increasing expenses over the next several years, principally to develop additional diagnostic tests, as well as to further increase our spending to manufacture, sell and market our products.

**Results of Operations Three months ended March 31, 2011 compared to the three months ended March 31, 2010*****Revenue***

	March 31,			
	2011	2010	\$ Change	% Change
Three months ended	\$ 757,869	\$ 409,783	\$ 348,086	85%

The increase in revenue for the three month period ended March 31, 2011 as compared to the three month period ended March 31, 2010 was primarily due to a \$308,000 increase in reagent revenue driven by the increase in number of our installed base of systems as well as an expanded menu of tests available for sale.

***Cost of Sales and Gross Loss***

	March 31,			
	2011	2010	\$ Change	% Change
Cost of Sales-three months ended	\$ 1,500,955	\$ 499,095	\$ 1,001,860	201%
Gross Loss -three months ended	\$ 743,086	\$ 89,312	\$ 653,774	732%

The increase in cost of sales for the three months ended March 31, 2011 compared to the three months ended March 31, 2010 was due to \$605,000 in increased expenses related directly to the increase in reagent and system shipments, as well as costs incurred in relocating our manufacturing facilities from Pasadena to our Carlsbad location in 2011, including \$314,000 in higher payroll, benefits and temporary labor costs and \$188,000 of additional facility-related charges. The increase in gross loss resulted primarily from costs associated with our expanded product offerings which will be reduced as a percentage of sales as our sales volume increases, and the one-time expense of relocating our manufacturing facility which should be completed by the end of the second quarter of 2011.

**Table of Contents***Operating Expenses**Sales and Marketing*

	March 31,			
	2011	2010	\$ Change	% Change
Three months ended	\$ 1,218,548	\$ 1,108,730	\$ 109,818	10%

The increase in sales and marketing expense was driven primarily by increased costs for product samples sent to prospective customers.

*General and Administrative*

	March 31,			
	2011	2010	\$ Change	% Change
Three months ended	\$ 2,123,054	\$ 2,180,494	\$ (57,440)	(3)%

General and administrative expense decreased for the three months ended March 31, 2011 compared to the three months ended March 31, 2010 due to \$925,000 in lower payroll, severance and other headcount related costs associated with our former UK operations and lower facility-related costs. These reductions were offset by a \$370,000 increase in professional services fees primarily related to corporate restructuring, and \$550,000 in additional consulting, share-based compensation and recruiting costs for executive services.

*Research and Development*

	March 31,			
	2011	2010	\$ Change	% Change
Three months ended	\$ 2,564,342	\$ 1,468,904	\$ 1,095,438	75%

The increase in research and development expense for the three months ended March 31, 2011 was due to \$150,000 in higher payroll expense due to increased headcount, severance related expenses of \$239,000, increased development supplies and clinical trial costs of \$160,000, a \$133,000 increase in intellectual property related costs, costs of \$250,000 incurred to obtain regulatory certification for our Carlsbad manufacturing facility and \$117,000 of increased facility related costs in 2011 as compared to the same period in 2010.



**Table of Contents****Other Income, Net**

	March 31,			
	2011	2010	\$ Change	% Change
Three months ended	\$ 18,157	\$ 3,544	\$ 14,613	412%

Interest and other income (expense) represent earnings on cash and cash equivalents and foreign currency gains or losses. The increase in revenue for the three months ended March 31, 2011 as compared to the same period in 2010 was due primarily to a foreign currency gain related to accounts receivable from the UK in 2010 that was received in 2011 at higher foreign currency translation rates. During the second quarter of 2010, the Company shut down its UK facility and changed its functional currency to the U.S. dollar. There are no remaining material operations in the UK.

**Provision for Income Taxes**

	March 31,			
	2010	2009	\$ Change	% Change
Three months ended	\$ 10,968	\$ 5,049	\$ 5,919	117%

Due to the Company's losses it has only recorded tax provisions or benefits related to interest on uncertain tax positions, minimum tax payments and refunds.

**Liquidity and Capital Resources**

To date we have funded our operations primarily from the sale of our common stock and revenues. We have incurred net losses from continuing operations each year and have not yet achieved profitability. At March 31, 2011, we had \$12.9 million of working capital, including \$17.1 million in cash and cash equivalents.

**Cash Flows**

The following table summarizes, for the periods indicated, selected items in our consolidated statements of cash flows:

	March 31,	
	2011	2010
Three months ended:		
Cash used by operating activities	\$ (3,090,451)	\$ (4,982,165)
Cash used by investing activities	(184,533)	(137,440)
Cash provided by financing activities	2,000,000	4,734
Decrease in cash and cash equivalents	\$ (1,274,984)	\$ (5,114,871)

**Cash flows used by operating activities**

Net cash used in operating activities decreased \$1.9 million to \$3.1 million for the three months ended March 31, 2011 compared to \$5.0 million for the three months ended March 31, 2010. The decreased use of cash was due primarily to collection of a \$1.6 million therapeutic tax credit and \$1.2 million of higher accounts payable and accrued liabilities in the current quarter, partially offset by accrued IPO costs at March 31, 2010 that were subsequently paid in 2010.

---

**Table of Contents**

*Cash flows used by investing activities*

Net cash used in investing activities increased \$48,000 to \$185,000 for the three months ended March 31, 2011 compared to \$137,000 for the three months ended March 31, 2010 primarily due to increased purchases of our XT-8 systems used for customer rentals which are included in property and equipment.

*Cash flows provided by financing activities*

Net cash provided by financing activities increased by \$2.0 million for the three months ended March 31, 2011 compared to the three months ended March 31, 2010 resulting from proceeds of a loan payable drawn in March 2011 to finance equipment purchases and tenant improvements purchased in 2010.

In March 2010, we entered into a loan and security agreement with Square 1 Bank, pursuant to which we obtained a credit facility consisting of a revolving line of credit in the amount of up to \$2 million and an equipment term loan in the amount of up to \$2 million. Based upon certain financial covenants, interest on the revolving line of credit will be either (i) the greater of (a) the bank's prime rate (3.25% as of March 31, 2011) plus 2.75%, or (b) 6%; or (ii) the greater of (a) the bank's prime rate plus 3.75%, or (b) 7%. In addition, based upon certain financial covenants, interest on the equipment term loan will be either (i) the greater of (a) the bank's prime rate plus 3.25%, or (b) 6.50%; or (ii) the greater of (a) the bank's prime rate plus 4.25%, or (b) 7.50%. The revolving line matures in July 2011 and the term loan matures in July 2013. In March 2011, the loan and security agreement was amended, whereby the line of credit availability was increased to \$3 million and the maturity was extended to July 2012. The term loan was modified to allow invoices up to 360 days to qualify to be submitted for credit extension. There were no other changes to these two loans.

In March 2011, an additional loan was made available under the amended loan and security agreement for up to \$1 million to finance equipment purchases. Based upon certain financial covenants, interest on this equipment term loan will be either (i) the greater of (a) the bank's prime rate plus 3.25%, or (b) 6.50%; or (ii) the greater of (a) the bank's prime rate plus 4.25%, or (b) 7.50%. This term loan matures March 2014.

As of March 31, 2011, the Company had no outstanding loans on the line of credit or the 2011 equipment loan and had drawn \$2.0 million to finance 2010 equipment purchases and tenant improvements to its Carlsbad facility against the original 2010 equipment term loan. The loan bears an interest rate of 6.5%. Interest-only payments at the rate of 6.5% are due monthly from the date of each initial equipment advance until July 12, 2011. Initial equipment advances that are then outstanding are payable in 24 equal monthly installments of principal, plus all accrued and unpaid interest, beginning on August 12, 2011 and continuing on the same day of each month thereafter through July 12, 2013.

Pursuant to the terms of the loan and security agreement, we are required to maintain a ratio of liquidity to bank indebtedness equal to at least 1.50 to 1.00. In addition, the loan and security agreement includes several restrictive covenants, including requirements that we obtain the consent of Square 1 Bank prior to entering into any change of control event unless all debt is repaid to Square 1 Bank prior to the change of control event, incurring other indebtedness or liens with respect to our property, making distributions to our stockholders, making certain investments or entering into certain transactions with affiliates and other restrictions on storing inventory and equipment with third parties. The agreement also limits the amount we can borrow under the term loan to license genetic biomarkers to \$500,000. To secure the credit facility, we granted Square 1 Bank a first priority security interest in our assets and intellectual property rights. We are currently in compliance with all ratios and covenants.

The Company's management has prepared cash flow forecasts which indicate, based on the current cash resources available, the availability of unutilized credit facilities, and our ability to access the equity markets will be sufficient to fund our business for at least the next 12 months. We expect capital outlays and operating expenditures to increase over the next several years as we grow our customer base and revenues, expand our research and development, commercialization and manufacturing activities. The amount of additional capital we may need to raise in the future depends on many factors, including:

the level of revenues and the rate of revenue growth;

the level of expenses required to expand our sales and marketing activities;



---

## **Table of Contents**

the level of research and development investment required to maintain and improve our technology;

our need to acquire or license complementary technologies or acquire complementary businesses;

the costs of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights;

competing technological and market developments; and

changes in regulatory policies or laws that affect our operations.

We cannot be certain that additional capital will be available when and as needed or that our actual cash requirements will not be greater than anticipated. If we require additional capital at a time when investment in diagnostics companies or in the marketplace in general is limited due to the then prevailing market or other conditions, we may not be able to raise such funds at the time that we desire, on acceptable terms, or at all. In addition, if we raise additional funds through the issuance of equity or convertible debt securities, the percentage ownership of our stockholders could be significantly diluted, and these newly issued securities may have rights, preferences or privileges senior to those of existing stockholders. If we obtain additional debt financing, a substantial portion of our operating cash flow may be dedicated to the payment of principal and interest on such indebtedness, and the terms of the debt securities issued could impose significant restrictions on our operations. If we raise additional funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our technologies or products, or grant licenses on terms that are not favorable to us.

### **Critical Accounting Policies and Estimates**

Our discussion and analysis of our financial condition and results of operations is based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, we evaluate our estimates including those related to bad debts, inventories, valuation of intangibles and other long-term assets, income taxes, and stock-based compensation. We base our estimates on historical experience and on various other assumptions we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities not readily apparent from other sources. Actual results may differ from these estimates. Our critical accounting policies and estimates are discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and there have been no material changes during the three months ended March 31, 2011.

### **Contractual Obligations**

On February 8, 2010, we entered into a seven-year and seven-month lease for a new 31,098 square foot facility in Carlsbad, California. The facility is part of a three-building office and research and development project located at 5964 La Place Court, Carlsbad, California, and the project totals 158,733 rentable square feet. Monthly rental payments of \$45,092 commenced on July 14, 2010 and increase 3% annually thereafter. We also pay our pro-rata share of the building and project maintenance, property tax, management and other costs subject to certain limitations. We have paid a \$55,000 security deposit and provided a \$500,000 standby letter of credit as security for the future rent as well as for up to \$2.0 million in landlord funded tenant improvements. The lease also provides for rights of first refusal for expansion within our building, subject to certain limitations.

On October 20, 2010, we entered into a licensing agreement for intellectual property. The agreement requires minimum payments of 1.0 million in four equal installments over two years and contains provisions for additional licensing fees of 1.25 million and additional royalties based on related product sales. The license terminates upon election by us as defined or termination of every patent and application of patent right included in the agreement or other material breach as defined in the contract.

On February 28, 2011, we entered into a 36 month operating lease for office equipment with total lease payments of \$85,000. In conjunction with the lease, the lessor paid the Company approximately \$27,000 to payoff previous contracts for similar equipment leased from a different vendor.



## **Table of Contents**

### **Other Off-Balance Sheet Arrangements**

We have no other off-balance sheet arrangements except for our unutilized credit facilities with Square 1 Bank that provides a revolving line of credit up to \$2 million and an unutilized equipment term loan totalling \$1 million at March 31, 2011.

### **ITEM 4. CONTROLS AND PROCEDURES**

#### ***Disclosure Controls and Procedures***

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934, as amended (Exchange Act), is recorded, processed, summarized and reported within the timelines specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Prior to the filing of our original Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 and under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (the Evaluation) at a reasonable assurance level as of the last day of the period covered by this report. Based upon the Evaluation, our Chief Executive Officer and Chief Financial Officer had concluded that our disclosure controls and procedures were effective at the reasonable assurance level. Subsequently, during the second quarter of 2011, we identified that some prior members of our finance and accounting department did not follow our internal control over financial reporting procedures. Specifically, members of our finance and accounting personnel did not effectively coordinate with members of our business development team regarding the terms of a license agreement. As a result of this failure, we failed to record certain intellectual property rights as both an asset and liability and, as a result, misstated our intangible assets in the periods identified in the Explanatory Note to this Amendment No. 1 on Form 10-Q/A. In addition, in the second quarter of 2011, we identified that some prior members of our finance team misclassified a number of operating expenses as costs of good sold and misclassified the current portion of a loan payable as long term debt. We believe that these misstatements and misclassifications, although immaterial to the prior periods in which they occurred, resulted from a deficiency in our internal control over financial reporting existing during these prior periods which constituted a material weakness in our internal control over financial reporting. Although the material weakness existed as of the fiscal year ended December 31, 2010, and as of the first quarter ended March 31, 2011, we did not discover the material weakness in our internal control over financial reporting until the second quarter of 2011, after the respective filing dates of our annual and quarterly reports. As a result of this discovery, our Chief Executive Officer and Chief Financial Officer have now concluded that our disclosure controls and procedures were not effective as of March 31, 2011.

#### ***Remediation of Material Weakness***

Unrelated to the discovery of the material weakness, we had previously hired a new Chief Executive Officer, Chief Financial Officer and Controller to lead our finance and accounting departments. Each of these individuals understands our system of internal controls, including our post-closing procedures which are designed to ensure our financial statements are prepared in accordance with generally accepted accounting principles. These new hires have also provided proper guidance and training on our internal control procedures to other finance and accounting personnel, many of which are also new hires. As a result, we have enhanced communication among our finance and accounting personnel and the personnel from our other departments. We believe these new hires will remediate the material weakness and that the financial statements included in this report fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented. No material weakness will be considered remediated, however, until any remedial procedures that we take have operated for an appropriate period, have been tested and management has concluded that they are operating effectively. In addition, we reviewed our processes and procedures for our internal control over financial reporting and we did not identify any additional controls with similar deficiencies. We have reviewed our assessment of the material weakness and our remediation and the status of its implementation and effectiveness with our audit committee.

#### ***Changes in Internal Control over Financial Reporting***

Except as otherwise discussed above, there has been no change in our internal control over financial reporting that occurred in the quarterly period covered by this report that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.



**Table of Contents**

**PART II-OTHER INFORMATION**

**ITEM 6. EXHIBITS.**

The exhibits listed in the Exhibit Index are incorporated herein by reference.



**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**GENMARK DIAGNOSTICS, INC.**

Date: December 2, 2011

/s/ Paul Ross  
**Paul Ross**  
**Chief Financial Officer**  
**(principal financial and accounting officer)**

---

**Table of Contents**

**EXHIBIT INDEX**

Listed and indexed below are all Exhibits filed as part of this report.

10.30#	Separation Agreement and General Release dated March 24, 2011, by and between Clinical Micro Sensors, Inc. d.b.a. GenMark Diagnostics, Inc. and Pankaj Singhal (incorporated by reference to Exhibit 10.1 on our Form 8-K filed with the Commission on March 28, 2010).
10.31#	Employee Offer Letter, dated March 11, 2011, by and between Clinical Micro Sensors, Inc. d.b.a. GenMark Diagnostics, Inc. and Paul Ross (incorporated by reference to Exhibit 10.1 on our Form 8-K/A filed with the Commission on April 7, 2011).
10.32*#	Executive Employment Agreement dated March 1, 2010, by and between Clinical Micro Sensors, Inc. d.b.a. GenMark Diagnostics, Inc. and Jeffrey Hawkins.
10.33*#	Executive Consulting Agreement dated October 12, 2010, by and between Clinical Micro Sensors, Inc. d.b.a. GenMark Diagnostics, Inc. and Kuranda Partners, LLC.
10.34*#	Executive Employment Agreement, dated April 5, 2011, by and between GenMark Diagnostics, Inc. and Hany Massarany.
31.1	Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended
31.2	Certification of Principal Financial Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.
32.1	Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. §1350.

\* Previously filed as an exhibit to GenMark Diagnostics, Inc. s. Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission for the quarter ended March 31, 2011

# Indicates management contract or compensatory plan.